An investigational Zika virus vaccine, TAK-426 (Takeda), has been granted Fast Track designation by the US Food and Drug Administration (FDA).

TAK-426 is a purified, inactivated, alum-adjuvanted, whole vaccine candidate. It is currently being assessed in a Phase 1 clinical trial to evaluate safety and immunogenicity (Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants; ZIK-101; NCT03343626). A total of 240 individuals between the ages of 18 and 49 have been enrolled in the trial. 

There is currently no vaccine for Zika and the World Health Organization says the virus has spread to 84 countries, including the US

Continue Reading

Related Articles


Takeda’s Zika vaccine candidate receives US FDA fast track designation [news release]. Osaka, Japan: Takeda Pharmaceutical Company. Published January 29, 2018. Accessed January 30, 2018

This article originally appeared on MPR